PL3806891T3 - Połączenie czynnika vii z przeciwciałami dwuswoistymi przeciwko czynnikowi ix oraz czynnikowi x - Google Patents

Połączenie czynnika vii z przeciwciałami dwuswoistymi przeciwko czynnikowi ix oraz czynnikowi x

Info

Publication number
PL3806891T3
PL3806891T3 PL19742443.5T PL19742443T PL3806891T3 PL 3806891 T3 PL3806891 T3 PL 3806891T3 PL 19742443 T PL19742443 T PL 19742443T PL 3806891 T3 PL3806891 T3 PL 3806891T3
Authority
PL
Poland
Prior art keywords
factor
combination
antibodies against
vii
dual antibodies
Prior art date
Application number
PL19742443.5T
Other languages
English (en)
Inventor
Jean-Luc Plantier
Original Assignee
Laboratoire Français Du Fractionnement Et Des Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62875040&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3806891(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoire Français Du Fractionnement Et Des Biotechnologies filed Critical Laboratoire Français Du Fractionnement Et Des Biotechnologies
Publication of PL3806891T3 publication Critical patent/PL3806891T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL19742443.5T 2018-06-14 2019-06-14 Połączenie czynnika vii z przeciwciałami dwuswoistymi przeciwko czynnikowi ix oraz czynnikowi x PL3806891T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1855239A FR3082427B1 (fr) 2018-06-14 2018-06-14 Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
PCT/FR2019/051456 WO2019239080A1 (fr) 2018-06-14 2019-06-14 Combinaison de facteur vii et d'un anticorps bispécifique anti-facteurs ix et x

Publications (1)

Publication Number Publication Date
PL3806891T3 true PL3806891T3 (pl) 2023-12-27

Family

ID=62875040

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19742443.5T PL3806891T3 (pl) 2018-06-14 2019-06-14 Połączenie czynnika vii z przeciwciałami dwuswoistymi przeciwko czynnikowi ix oraz czynnikowi x

Country Status (24)

Country Link
US (1) US20220152197A9 (pl)
EP (1) EP3806891B2 (pl)
JP (2) JP7560364B2 (pl)
KR (1) KR20210020091A (pl)
CN (2) CN120037366A (pl)
AU (1) AU2019285324B2 (pl)
BR (1) BR112020025529A2 (pl)
CA (1) CA3103028A1 (pl)
CO (1) CO2021000087A2 (pl)
DK (1) DK3806891T3 (pl)
ES (1) ES2956309T3 (pl)
FI (1) FI3806891T3 (pl)
FR (1) FR3082427B1 (pl)
HR (1) HRP20231109T1 (pl)
HU (1) HUE063593T2 (pl)
MX (1) MX2020013657A (pl)
MY (1) MY206087A (pl)
PL (1) PL3806891T3 (pl)
PT (1) PT3806891T (pl)
RS (1) RS64646B1 (pl)
SI (1) SI3806891T1 (pl)
SM (1) SMT202300301T1 (pl)
WO (1) WO2019239080A1 (pl)
ZA (1) ZA202008030B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811526T3 (es) 2010-12-30 2021-03-12 Lab Francais Du Fractionnement Glicoles como agentes de inactivación de patógenos
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
KR20230146147A (ko) 2022-04-11 2023-10-19 주식회사 아단소니아 장기 세포 추적용 형광 물질
CN116143929B (zh) * 2023-02-03 2023-08-01 北京基科晟斯医药科技有限公司 抗重组人凝血因子VIIa-Fc融合蛋白的抗体及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
FR2677652B1 (fr) 1991-06-12 2005-05-27 Agronomique Inst Nat Rech Procede de preparation d'une proteine d'interet dans le lait d'un animal transgenique, produit obtenu et cellule eucaryote utilisee.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
GB0311465D0 (en) * 2003-05-19 2003-06-25 Nat Inst Biological Standards & Control Composition
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
PT1876236E (pt) 2005-04-08 2014-10-22 Chugai Pharmaceutical Co Ltd Anticorpos para substituição da função do factor de coagulação sanguínea viii
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
US20110059510A1 (en) 2008-03-25 2011-03-10 Pierre-Jean Ripoll Transgenic rabbits producing human factor vii
FR2947181B1 (fr) 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
EP2687595B1 (en) * 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
JP6698102B2 (ja) * 2015-04-17 2020-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 凝固因子と多重特異的抗体を用いた併用療法
WO2017110980A1 (ja) * 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
WO2017126488A1 (ja) * 2016-01-18 2017-07-27 持田製薬株式会社 乾癬治療用組成物および治療方法
CR20180554A (es) 2016-04-28 2019-01-10 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos
PL3509637T3 (pl) 2016-09-06 2025-03-10 Chugai Seiyaku Kabushiki Kaisha Sposoby zastosowania dwuswoistego przeciwciała, które rozpoznaje czynnik krzepnięcia IX i/lub aktywowany czynnik krzepnięcia IX oraz czynnik krzepnięcia X i/lub aktywowany czynnik krzepnięcia X
TN2019000164A1 (en) * 2016-11-23 2020-10-05 Bioverativ Therapeutics Inc Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
JP2017189647A (ja) 2017-07-19 2017-10-19 株式会社三洋物産 遊技機
PE20210005A1 (es) 2017-09-29 2021-01-05 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo

Also Published As

Publication number Publication date
EP3806891A1 (fr) 2021-04-21
HUE063593T2 (hu) 2024-01-28
FR3082427A1 (fr) 2019-12-20
PT3806891T (pt) 2023-09-07
US20210275668A1 (en) 2021-09-09
ES2956309T3 (es) 2023-12-19
FR3082427B1 (fr) 2020-09-25
ZA202008030B (en) 2022-08-31
US20220152197A9 (en) 2022-05-19
CN112584855B (zh) 2025-03-07
WO2019239080A1 (fr) 2019-12-19
CN120037366A (zh) 2025-05-27
EP3806891B1 (fr) 2023-08-02
MX2020013657A (es) 2021-03-02
DK3806891T3 (da) 2023-09-25
HRP20231109T1 (hr) 2023-12-22
MY206087A (en) 2024-11-28
AU2019285324B2 (en) 2026-01-08
JP2021527644A (ja) 2021-10-14
SI3806891T1 (sl) 2023-11-30
SMT202300301T1 (it) 2024-01-10
RS64646B1 (sr) 2023-10-31
JP2024096477A (ja) 2024-07-12
KR20210020091A (ko) 2021-02-23
CO2021000087A2 (es) 2021-01-29
BR112020025529A2 (pt) 2021-03-09
CA3103028A1 (fr) 2019-12-19
JP7560364B2 (ja) 2024-10-02
AU2019285324A1 (en) 2021-01-14
EP3806891B2 (fr) 2026-03-04
FI3806891T3 (fi) 2023-09-20
CN112584855A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
IL289354A (en) Anti-cd154 antibodies and uses thereof
IL283550A (en) Chemically-modified rnai constructs and uses thereof
PT3802608T (pt) Anticorpos anti-cd3 e utilizações destes
PL3618928T3 (pl) Przeciwciała antysortylinowe i sposoby ich stosowania
PL3601358T3 (pl) Przeciwciała anty-trem2 i sposoby ich wykorzystania
EP3740224A4 (en) ANTI-LILRB ANTIBODIES AND THEIR USES
IL280317A (en) Anti-avb8 antibodies and compositions and uses thereof
PL3383916T3 (pl) Przeciwciała anty-cd73 i ich zastosowania
IL262095A (en) Anti-pacap antibodies and uses thereof
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
IL284561A (en) Prostate neoantigens and their uses
IL259747A (en) Antibodies targeting fc receptor-like 5 and methods of use
IL279937A (en) Variants of cd38 antibody and uses thereof
IL269122A (en) Anti-c5 antibodies and uses thereof
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
PT3274370T (pt) Anticorpos anti-ceacam6 e utilizações dos mesmos
EP3904382A4 (en) ANTI-IL-23P19 ANTIBODIES AND ITS USES
EP4071172A4 (en) ANTI-LILRB1 ANTIBODIES AND ITS USES
IL285401A (en) Anti-clec2d antibodies and methods of use thereof
IL263273A (en) Anti-gitr antibodies and uses thereof
IL281297A (en) Anti-npr1 antibodies and uses thereof
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL271398A (en) Anti-l1-cam antibodies and uses thereof
IL283782A (en) Anellosomes and methods of use
IL286641A (en) Engineered iga antibodies and methods of use